medwireNews: Sacituzumab govitecan has been given accelerated approval from the US FDA for previously treated locally advanced or metastatic urothelial cancer.
The Trop-2-directed antibody–drug conjugate is indicated for patients who have progressed on a platinum-based chemotherapy regimen and a PD-1 or PD-L1 inhibitor. However, “[c]ontinued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial,” states the press release.
The decision was based on results from the TROPHY U-01 trial, which showed an objective response rate of 27.7% – consisting of complete responses in 5.4% of patients – and a median duration of response of 7.2 months in this patient population.
According to the prescribing information, sacituzumab govitecan should be given at a dose of 10 mg/kg on days 1 and 8 of each 21-day treatment cycle, which is also the dose recommended for use in the refractory metastatic triple-negative breast cancer setting.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group